03:56 AM EDT, 06/09/2026 (MT Newswires) -- Zai Lab ( ZLAB ) received approval from China's National Medical Products Administration for Tivdak to treat adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy, the company said Monday.

The approval was supported by results from a phase 3 trial in which Tivdak showed a 45% reduction in the risk of death compared to chemotherapy in the China subpopulation, Zai Lab ( ZLAB ) said.